Rosmarinic acid protects against experimental sepsis by inhibiting proinflammatory factor release and ameliorating hemodynamics

Shock

Volumn 32, Issue 6, 2009, Pages 608-613

  Jiang, Wang Lin ^a,b   Chen, Xi Guang ^a   Qu, Gui Wu ^b   Yue, Xi Dian ^b   Zhu, Hai Bo ^b   Tian, Jing Wei ^b   Fu, Feng Hua ^b  

^a OCEAN UNIVERSITY OF CHINA   (China)

^b YANTAI UNIVERSITY   (China)

Author keywords

Cecal ligation and puncture; High mobility group box 1 protein; Il 10; Il 6; Nf .b; Rosmarinic acid; Septic shock; Triggering receptor expressed on myeloid cells

Indexed keywords

CYTOKINE; ENDOTOXIN; HIGH MOBILITY GROUP B1 PROTEIN; I KAPPA B KINASE; IMIPENEM; INTERLEUKIN 6; LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDE; ROSMARINIC ACID; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; ENZYME RELEASE; EXPERIMENTAL MODEL; INFLAMMATION; MORTALITY; NONHUMAN; SEPSIS; SEPTIC SHOCK; SURVIVAL TIME; TOXICITY TESTING; TREATMENT OUTCOME; WESTERN BLOTTING;

ANIMALS; ANTI-BACTERIAL AGENTS; CINNAMATES; DEPSIDES; DISEASE MODELS, ANIMAL; ENDOTOXINS; GENE EXPRESSION REGULATION; HEMODYNAMICS; HUMANS; IMIPENEM; INFLAMMATION; MALE; MICE; MYELOID CELLS; RATS; RATS, SPRAGUE-DAWLEY; SEPSIS; TRETINOIN;

EID: 73849085921     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3181a48e86     Document Type: Article

References (34)

1. Bochud PY, Calandra T: Pathogenesis of sepsis: new concepts and implications for future treatment. Br J Med 326(7283):262-266, 2003.
2. Bone RC: Pathophysiology of sepsis. Ann Intern Med 115(6):457-469, 1991.
3. Yethon JA, Whitfield C: Lipopolysaccharide as a target for the development of novel therapeutics in gram-negative bacteria. Curr Drug Targets Infect Disord 1(2):91-106, 2001.
4. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29(7):1303-1310, 2001.
5. Edgeworth JD, Treacher DF, Eykyn SJ: A 25-year study of nosocomial bac-teremia in an adult intensive care unit. Crit Care Med 27(8):1421-1428, 1999.
6. Cohen J: The immunopathogenesis of sepsis. Nature 42(6917):885-891, 2002.
7. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J: HMG-1 as a late mediator of endotoxin lethality in mice. Science 285(5425): 248-251, 1999.
8. Andersson U, Tracey KJ: HMGB1 in sepsis. Scand J Infect Dis 35(9): 577-584, 2003.
9. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH: Inflammation-promoting activity of HMGB1 on human microvascular endo-thelial cells. Blood 101(7):2652-2660, 2003.
10. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, Sohn JW: High mobility group box 1 protein interacts with multiple Toll like receptors. Am J Physiol Cell Physiol 290(3):917-924, 2006.
11. Kokkola R, Andersson A, Mullins G, Ostberg T, Treutiger CJ, Arnold B, Nawroth P: RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 61(1):1-9, 2005.
12. Zhang LT, Yao YM, Lu JQ, Yan XJ, Yu Y, Sheng ZY: Recombinant bactericidal/permeability-increasing protein inhibits endotoxin-induced high-mobility group box 1 protein gene expression in sepsis. Shock 29(2):278-284, 2008.
13. Hagiwara S, Iwasaka H, Maeda H, Noguchi T: Landiolol, an ultra shortYacting beta 1Yadernoceptor antagonist has protective effects in a LPS-induced systemic inflammation model. Shock 31(5):515-520, 2009.
14. Zhang LT, Yao YM, Lu JQ, Yan XJ, Yu Y, Sheng ZY: Sodium butyrate prevents lethality of severe sepsis in rats. Shock 27(6):672-677, 2007.
15. Takeda H, Tsuji M, Inazu M, Egashira T, Matsumiya T: Rosmarinic acid and caffeic acid produce antidepressive-like effect in the forced swimming test in mice. Eur J Pharmacol 449(3):261-267, 2002.
16. Osakabe N, Yasuda A, Natsume M, Sanbongi C, Kato Y, Osawa T, Yoshikawa T: Rosmarinic acid, a major polyphenolic component of Perilla frutescens, reduces lipopolysaccharide (LPS)-induced liver injury in D-galactosamine (D-GalN)Ysensitized mice. Free Radic Biol Med 33(6):798-806, 2002.
17. Osakabe N, Yasuda A, Natsume M, Yoshikawa T: Rosmarinic acid inhibits epidermal inflammatory responses: anticarcinogenic effect of Perilla frutescens extract in the murine two-stage skin model. Carcinogenesis 25(4):549-557, 2004.
18. Huang SS, Zheng RL: Rosmarinic acid inhibits angiogenesis and its mechanism of action in vitro. Cancer Lett 239(2):271-280, 2006.
19. McKay DL, Blumberg JB: A review of the bioactivity and potential health benefits of peppermint tea (Mentha piperita L). Phytother Res 20(8):619-633, 2006.
20. Dubois M, Bailly F, Mbemba G, Mouscadet JF, Debyser Z, Witvrouw M, Cotelle P: Reaction of rosmarinic acid with nitrite ions in acidic conditions: discovery of nitro-and dinitrorosmarinic acids as new antiYHIV-1 agents. J Med Chem 51(8):2575-2579, 2008.
21. Kosar M, Göger F, Can Baser KH: In vitro antioxidant properties and phenolic composition of Salvia virgata Jacq from Turkey. J Agric Food Chem 56(7):2369-2374, 2008.
22. Won JH, Kim YH, Yun KJ, Park HJ, Choi JW, Lee KT: Anti-inflammatory effect of buddlejasaponin IV through the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via the NF-kappaB inactivation. Br J Pharmacol 148(2):216-225, 2006.
23. Wang Y, Chen T, Han C, He D, Liu H, An H: Lysosome-associated small Rab GTPase Rab7b negatively regulates TLR4 signaling in macrophages by promoting lysosomal degradation of TLR4. Blood 110(3):962-971, 2007.
24. Gibot S, Massin F, Marcou M, Taylor V, Stidwill R, Wilson P: TREM-1 promotes survival during septic shock in mice. Eur J Immunol 37(2):456-466, 2007.
25. Mansart A, Bollaert PE, Seguin C, Levy B, Longrois D, Mallie JP: Hemo-dynamic effects of early versus late glucocorticosteroid administration in experimental septic. Shock 19(1):38-44, 2003.
26. Bradley PP, Christensen RD, Rothstein G: Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78(3):206-209, 1982.
27. William JH, Mashkoor C, Martin GS, Jeffrey DK, Loring WR, Kirby IB: Cecal ligation and puncture. Shock 24(Suppl 1):52-57, 2005.
28. Chin Hsu, Guang Wu, Shaw LY, Hseng KH, Rei CY, Cha SHT, Maw SHL: Intracellular redistribution of dihydropyridine receptor in the rat heart during the progression of sepsis. J Surg Res 141(2):146-152, 2007.
29. Liu CL, Hsieh WY, Wu CL, Kuo HT, Lu YT: Triggering receptor expressed on myeloid cellsY1 in pleural effusions: a marker of inflammatory disease. Resp Med 101(5):903-909, 2007.
30. Bouchon A, Facchetti F, Weigand MA, Colonna M: TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 410(6832): 1103-1107, 2001.
31. Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM: The dual role of IL-10. Trends Immunol 24(1):36-43, 2003.
32. Kadoi Y, Goto F: Effects of selective iNOS inhibition on systemic hemo-dynamics and mortality rate on endotoxic shock in streptozotocin-induced diabetic rats. Shock 28(5):602-609, 2007.
33. Wheeler DS, Lahni PM, Hake PW, Denenberg AG, Wong HR, Snead C: The green tea polyphenol epigallocatechin-3-gallate improves systemic hemody-namics and survival in rodent models of polymicrobial sepsis. Shock 28(3): 353-359, 2007.
34. Nitescu N, Grimberg E, Guron G: Low-dose candesartan improves renal blood flow and kidney oxygen tension in rats with endotoxin-induced acute kidney dysfunction. Shock 30(2):166-172, 2008